|
|
Line 168: |
Line 168: |
| </article> | | </article> |
| <article> | | <article> |
− | <a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/d/dc/Diagram_Models_.jpg" title="Click to return back to the top." /></a> | + | <a href="#" class="image"><img src="https://static.igem.org/mediawiki/2017/5/54/Raprapanchiegg.jpg" title="Click to return back to the top." /></a> |
| <h3 class="major">Figure 3</h3> | | <h3 class="major">Figure 3</h3> |
| <p>Our promoter-reporter construct is built so that only when there is both COX-2 and c-Myc will the binding sites be able to come together and glow with the addition of rapamycin. The construct built to bind with COX-2 consists of a COX-2 promoter, FKBP, c-Luc, and terminator. The construct built to bind with c-Myc consists of a c-Myc promoter, FRB, n-Luc, and terminator.</p> | | <p>Our promoter-reporter construct is built so that only when there is both COX-2 and c-Myc will the binding sites be able to come together and glow with the addition of rapamycin. The construct built to bind with COX-2 consists of a COX-2 promoter, FKBP, c-Luc, and terminator. The construct built to bind with c-Myc consists of a c-Myc promoter, FRB, n-Luc, and terminator.</p> |